TRADES
Latest Trades
3239
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKK 27 Jan 2023 Sell MTLS MATERIALISE NV 126,153 0.0171
ARKK 27 Jan 2023 Sell EXAS EXACT SCIENCES CORP 156,704 0.1395
ARKK 26 Jan 2023 Buy TDOC TELADOC INC 99,464 0.0373
ARKK 26 Jan 2023 Buy NTLA INTELLIA THERAPEUTICS INC 147,825 0.0786
ARKK 26 Jan 2023 Sell MTLS MATERIALISE NV 31,509 0.0043
ARKK 26 Jan 2023 Sell EXAS EXACT SCIENCES CORP 6,624 0.0059
ARKK 25 Jan 2023 Sell MTLS MATERIALISE NV 34,520 0.0047
ARKK 25 Jan 2023 Sell EXAS EXACT SCIENCES CORP 458,427 0.4041
ARKK 24 Jan 2023 Sell EXAS EXACT SCIENCES CORP 63,674 0.0574
ARKK 23 Jan 2023 Buy TSLA TESLA INC 13,243 0.0273
ARKK 23 Jan 2023 Buy TDOC TELADOC INC 49,418 0.0194
ARKK 23 Jan 2023 Buy NTLA INTELLIA THERAPEUTICS INC 8,770 0.0044
ARKK 23 Jan 2023 Sell EXAS EXACT SCIENCES CORP 111,615 0.1098
ARKK 18 Jan 2023 Buy TSLA TESLA INC 32,447 0.0613
ARKK 18 Jan 2023 Sell MTLS MATERIALISE NV 11,185 0.0016
ARKK 17 Jan 2023 Buy TSLA TESLA INC 73,461 0.1387
ARKK 17 Jan 2023 Sell MTLS MATERIALISE NV 217,172 0.0309
ARKK 17 Jan 2023 Sell EXAS EXACT SCIENCES CORP 138,180 0.1376
ARKK 13 Jan 2023 Buy TSLA TESLA INC 168,989 0.2996
ARKK 13 Jan 2023 Sell MTLS MATERIALISE NV 200,609 0.0273
ARKK 13 Jan 2023 Sell EXAS EXACT SCIENCES CORP 291,758 0.2955
ARKK 12 Jan 2023 Buy COIN COINBASE GLOBAL INC 52,813 0.0342
ARKK 11 Jan 2023 Buy TSLA TESLA INC 69,060 0.1318
ARKK 11 Jan 2023 Sell MTLS MATERIALISE NV 522,936 0.0744
ARKK 11 Jan 2023 Buy COIN COINBASE GLOBAL INC 74,792 0.0491
ARKK 10 Jan 2023 Buy TSLA TESLA INC 75,565 0.1424
ARKK 10 Jan 2023 Sell NVDA NVIDIA CORP 125 0.0003
ARKK 10 Jan 2023 Sell MTLS MATERIALISE NV 280,869 0.0401
ARKK 10 Jan 2023 Sell FATE FATE THERAPEUTICS INC 1,125 0.0001
ARKK 10 Jan 2023 Sell EXAS EXACT SCIENCES CORP 320,395 0.3049
ARKK 10 Jan 2023 Buy COIN COINBASE GLOBAL INC 33,756 0.0222
ARKK 9 Jan 2023 Buy TSLA TESLA INC 11,405 0.0231
ARKK 9 Jan 2023 Sell NVDA NVIDIA CORP 4,036 0.0104
ARKK 9 Jan 2023 Sell MTLS MATERIALISE NV 95,892 0.0140
ARKK 9 Jan 2023 Sell FATE FATE THERAPEUTICS INC 35,380 0.0026
ARKK 6 Jan 2023 Buy TSLA TESLA INC 24,506 0.0465
ARKK 6 Jan 2023 Sell NVDA NVIDIA CORP 31,758 0.0777
ARKK 6 Jan 2023 Sell MTLS MATERIALISE NV 11,110 0.0016
ARKK 6 Jan 2023 Sell FATE FATE THERAPEUTICS INC 19,096 0.0014
ARKK 4 Jan 2023 Buy TSLA TESLA INC 17,430 0.0332
ARKK 4 Jan 2023 Sell MTLS MATERIALISE NV 296,438 0.0440
ARKK 4 Jan 2023 Sell FATE FATE THERAPEUTICS INC 204,154 0.0386
ARKK 3 Jan 2023 Buy TSLA TESLA INC 144,776 0.2609
ARKK 3 Jan 2023 Sell MTLS MATERIALISE NV 48,732 0.0073
ARKK 3 Jan 2023 Sell FATE FATE THERAPEUTICS INC 1,150,274 0.1960
ARKK 30 Dec 2022 Buy TSLA TESLA INC 221,748 0.4476
ARKK 30 Dec 2022 Sell MTLS MATERIALISE NV 70,330 0.0103
ARKK 30 Dec 2022 Sell FATE FATE THERAPEUTICS INC 1,915,846 0.3173
ARKK 29 Dec 2022 Buy ZM ZOOM VIDEO COMMUNICATIONS 56,808 0.0670
ARKK 29 Dec 2022 Buy TSLA TESLA INC 22,514 0.0473
ARKK 29 Dec 2022 Buy TDOC TELADOC INC 166,294 0.0689
ARKK 29 Dec 2022 Buy ROKU ROKU INC 32,011 0.0226
ARKK 29 Dec 2022 Sell MTLS MATERIALISE NV 142,169 0.0218
ARKK 29 Dec 2022 Sell FATE FATE THERAPEUTICS INC 2,822,583 0.4897
ARKK 29 Dec 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 3,680,886 0.1071
ARKK 28 Dec 2022 Buy TSLA TESLA INC 17,960 0.0345
ARKK 28 Dec 2022 Sell MTLS MATERIALISE NV 44,042 0.0065
ARKK 28 Dec 2022 Sell FATE FATE THERAPEUTICS INC 142,110 0.0244
ARKK 27 Dec 2022 Buy TSLA TESLA INC 25,147 0.0462
ARKK 27 Dec 2022 Sell MTLS MATERIALISE NV 3,946 0.0006
ARKK 27 Dec 2022 Sell FATE FATE THERAPEUTICS INC 277,522 0.0463
ARKK 23 Dec 2022 Buy TSLA TESLA INC 20,458 0.0404
ARKK 23 Dec 2022 Buy ROKU ROKU INC 6,786 0.0045
ARKK 23 Dec 2022 Sell FATE FATE THERAPEUTICS INC 136,762 0.0241
ARKK 23 Dec 2022 Sell EXAS EXACT SCIENCES CORP 26,840 0.0225
ARKK 22 Dec 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 26,329 0.0007
ARKK 21 Dec 2022 Buy ZM ZOOM VIDEO COMMUNICATIONS 486 0.0005
ARKK 21 Dec 2022 Buy TSLA TESLA INC 9,952 0.0217
ARKK 21 Dec 2022 Buy SQ BLOCK INC 1,932 0.0019
ARKK 21 Dec 2022 Buy ROKU ROKU INC 8,004 0.0054
ARKK 21 Dec 2022 Sell MTLS MATERIALISE NV 22,260 0.0031
ARKK 21 Dec 2022 Sell FATE FATE THERAPEUTICS INC 130,138 0.0259
ARKK 20 Dec 2022 Buy TSLA TESLA INC 19,125 0.0421
ARKK 20 Dec 2022 Sell MTLS MATERIALISE NV 847 0.0001
ARKK 20 Dec 2022 Sell EXAS EXACT SCIENCES CORP 32,910 0.0268
ARKK 19 Dec 2022 Buy VERV VERVE THERAPEUTICS INC 38,421 0.0106
ARKK 19 Dec 2022 Buy TWST TWIST BIOSCIENCE CORP 4,611 0.0016
ARKK 19 Dec 2022 Buy TDOC TELADOC INC 50,037 0.0195
ARKK 19 Dec 2022 Buy SQ BLOCK INC 9,372 0.0085
ARKK 19 Dec 2022 Buy ROKU ROKU INC 68,079 0.0446
ARKK 19 Dec 2022 Buy NTLA INTELLIA THERAPEUTICS INC 10,867 0.0057
ARKK 19 Dec 2022 Sell EXAS EXACT SCIENCES CORP 114,174 0.0893
ARKK 19 Dec 2022 Buy CRSP CRISPR THERAPEUTICS AG 17,738 0.0118
ARKK 19 Dec 2022 Buy BEAM BEAM THERAPEUTICS INC 23,816 0.0144
ARKK 16 Dec 2022 Buy ZM ZOOM VIDEO COMMUNICATIONS 32,773 0.0338
ARKK 16 Dec 2022 Buy VERV VERVE THERAPEUTICS INC 5,759 0.0016
ARKK 16 Dec 2022 Sell VCYT VERACYTE INC 18,274 0.0075
ARKK 16 Dec 2022 Buy TWST TWIST BIOSCIENCE CORP 3,385 0.0012
ARKK 16 Dec 2022 Buy TSLA TESLA INC 31,018 0.0690
ARKK 16 Dec 2022 Buy TDOC TELADOC INC 13,382 0.0053
ARKK 16 Dec 2022 Buy SQ BLOCK INC 20,632 0.0187
ARKK 16 Dec 2022 Buy ROKU ROKU INC 37,524 0.0254
ARKK 16 Dec 2022 Buy NTLA INTELLIA THERAPEUTICS INC 7,844 0.0042
ARKK 16 Dec 2022 Sell MTLS MATERIALISE NV 30,991 0.0042
ARKK 16 Dec 2022 Sell EXAS EXACT SCIENCES CORP 190,416 0.1488
ARKK 16 Dec 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 46,178 0.0012
ARKK 16 Dec 2022 Buy CRSP CRISPR THERAPEUTICS AG 10,842 0.0073
ARKK 16 Dec 2022 Buy BEAM BEAM THERAPEUTICS INC 693 0.0004
ARKK 15 Dec 2022 Buy VERV VERVE THERAPEUTICS INC 37,163 0.0104
ARKK 15 Dec 2022 Sell VCYT VERACYTE INC 37,746 0.0151
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.